Newron secured €38m to test a potential new class in schizophrenia

EUROPEAN BIOTECHNOLOGY MAGAZINE - Newron Pharmaceuticals has secured up to €38mn to advance Phase III trials of evenamide, a drug that, if successful, could represent one of the first circuit-modulating therapies in schizophrenia. Read more

Photo: George C, for Unsplash+